Substrate Report for: Valacyclovir
Valacyclovir | Type | Purine |
| | Drug |
| | Not A/B H target |
| | Nucleoside |
| Other_Name | Valaciclovir |
| | Valtrex |
| | Zelitrex |
| | ValACV |
| Chemical_Nomenclature | 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate |
| | 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate |
| Formula | C13H20N6O4 |
| CAS_number | 124832-26-4 |
| MW | 324.33 |
| |
| Paper (5) |
| Comment | Valacyclovir is an ester of acyclovir a Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor. Orally administered, valacyclovir is rapidly converted by Valacyclovir hydrolase a biphenyl hydrolase-like |
| Gene_locus | human-BPHL |
| | mouse-bphl |
| CID | 60773 |
| | 135398742 |
| Family | Valacyclovir-hydrolase |
| InChIKey | HDOVUKNUBWVHOX-QMMMGPOBSA-N |
| CanonicalSMILES | CC(C)C(C(=O)OCCOCN1C=NC2=C1NC(=NC2=O)N)N |
| | CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N |
| InChI | InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1 |
| IupharLig | 4824 |
| Wikipedia | Valacyclovir |
|
|